Botulinum Toxin Intervention in Cerebral Palsy-Induced Spasticity Management: Projected and Contradictory Effects on Skeletal Muscles

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2022 Nov 10

PMID 36356022

Authors

Cemre Su Kaya Keles

Filiz Ates

Affiliations

Soon will be listed here.

Abstract

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a pathological condition, the central feature of which is involuntary and prolonged muscle contraction. The persistent resistance of spastic muscles to stretching is often followed by structural and mechanical changes in musculature. This leads to functional limitations at the respective joint. Focal injection of botulinum toxin type-A (BTX-A) is effectively used to manage spasticity and improve the quality of life of the patients. By blocking acetylcholine release at the neuromuscular junction and causing temporary muscle paralysis, BTX-A aims to reduce spasticity and hereby improve joint function. However, recent studies have indicated some contradictory effects such as increased muscle stiffness or a narrower range of active force production. The potential of these toxin- and atrophy-related alterations in worsening the condition of spastic muscles that are already subjected to changes should be further investigated and quantified. By focusing on the effects of BTX-A on muscle biomechanics and overall function in children with CP, this review deals with which of these goals have been achieved and to what extent, and what can await us in the future.

Citing Articles

Chinese herbal medicine for the treatment of children with cerebral palsy: a meta-analysis of randomized controlled trials with core herbs exploration.

Huang Y, Cheng Y, Chen H, Fu R, Chang Y, Yang T Front Pharmacol. 2025; 16:1500095.

PMID: 40078275 PMC: 11897310. DOI: 10.3389/fphar.2025.1500095.

Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapies.

Rahmatipour H, Shabestari S, Benisi S, Samadikhah H Heliyon. 2025; 11(4):e42350.

PMID: 40028584 PMC: 11870196. DOI: 10.1016/j.heliyon.2025.e42350.

The effectiveness of non-invasive brain stimulation in enhancing lower extremity function in children with spastic cerebral palsy: Protocol for a systematic review and meta-analysis.

Arumi-Trujillo C, Verdejo-Amengual F, Martinez-Navarro O, Vink J, Valenzuela-Pascual F MethodsX. 2025; 14():103141.

PMID: 39850763 PMC: 11755019. DOI: 10.1016/j.mex.2024.103141.

A Case Report of Cryoneurolysis With Factor VIII Administration for Cerebral Palsy-related Spasticity in a Patient With Hemophilia A.

Mumby G, Schatz L, Claridge E, Hashemi M, Winston P Adv Rehabil Sci Pract. 2025; 14():27536351241311802.

PMID: 39823092 PMC: 11733879. DOI: 10.1177/27536351241311802.

Efficacy, Indications, and Safety of Intrathecal Baclofen Pump: A Narrative Review.

Kaye A, Cheon S, Roque M, Gibbs C, Mott K, Wandler A Curr Pain Headache Rep. 2025; 29(1):9.

PMID: 39754631 DOI: 10.1007/s11916-024-01310-x.

References

Haubruck P, Mannava S, Plate J, Callahan M, Wiggins W, Schmidmaier G . Botulinum Neurotoxin A injections influence stretching of the gastrocnemius muscle-tendon unit in an animal model. Toxins (Basel). 2012; 4(8):605-19. PMC: 3446746. DOI: 10.3390/toxins4080605. View

Hanssen B, Peeters N, Vandekerckhove I, De Beukelaer N, Bar-On L, Molenaers G . The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy. Front Neurol. 2021; 12:692582. PMC: 8350776. DOI: 10.3389/fneur.2021.692582. View

Turkoglu A, Huijing P, Yucesoy C . Mechanical principles of effects of botulinum toxin on muscle length-force characteristics: an assessment by finite element modeling. J Biomech. 2014; 47(7):1565-71. DOI: 10.1016/j.jbiomech.2014.03.017. View

Barrett R, Lichtwark G . Gross muscle morphology and structure in spastic cerebral palsy: a systematic review. Dev Med Child Neurol. 2010; 52(9):794-804. DOI: 10.1111/j.1469-8749.2010.03686.x. View

Ates F, Temelli Y, Yucesoy C . Effects of antagonistic and synergistic muscles' co-activation on mechanics of activated spastic semitendinosus in children with cerebral palsy. Hum Mov Sci. 2017; 57:103-110. DOI: 10.1016/j.humov.2017.11.011. View

Yucesoy C, Turkoglu A, Umur S, Ates F . Intact muscle compartment exposed to botulinum toxin type A shows compromised intermuscular mechanical interaction. Muscle Nerve. 2014; 51(1):106-16. DOI: 10.1002/mus.24275. View

Kasper C, Xun L . Expression of titin in skeletal muscle varies with hind-limb unloading. Biol Res Nurs. 2001; 2(2):107-15. DOI: 10.1177/109980040000200204. View

Turner-Stokes L, Ashford S, Jacinto J, Maisonobe P, Balcaitiene J, Fheodoroff K . Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III). BMJ Open. 2016; 6(6):e011157. PMC: 4916608. DOI: 10.1136/bmjopen-2016-011157. View

Maas H, Baan G, Huijing P . Intermuscular interaction via myofascial force transmission: effects of tibialis anterior and extensor hallucis longus length on force transmission from rat extensor digitorum longus muscle. J Biomech. 2001; 34(7):927-40. DOI: 10.1016/s0021-9290(01)00055-0. View

10.

Picelli A, Santamato A, Chemello E, Cinone N, Cisari C, Gandolfi M . Adjuvant treatments associated with botulinum toxin injection for managing spasticity: An overview of the literature. Ann Phys Rehabil Med. 2018; 62(4):291-296. DOI: 10.1016/j.rehab.2018.08.004. View

11.

Fortuna R, Vaz M, Rehan Youssef A, Longino D, Herzog W . Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). J Biomech. 2010; 44(1):39-44. DOI: 10.1016/j.jbiomech.2010.08.020. View

12.

Ganguly J, Kulshreshtha D, Almotiri M, Jog M . Muscle Tone Physiology and Abnormalities. Toxins (Basel). 2021; 13(4). PMC: 8071570. DOI: 10.3390/toxins13040282. View

13.

Shortland A, Harris C, Gough M, Robinson R . Architecture of the medial gastrocnemius in children with spastic diplegia. Dev Med Child Neurol. 2002; 44(3):158-63. DOI: 10.1017/s0012162201001864. View

14.

Yaraskavitch M, Leonard T, Herzog W . Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech. 2008; 41(4):897-902. DOI: 10.1016/j.jbiomech.2007.11.016. View

15.

Papavasiliou A . Management of motor problems in cerebral palsy: a critical update for the clinician. Eur J Paediatr Neurol. 2008; 13(5):387-96. DOI: 10.1016/j.ejpn.2008.07.009. View

16.

Ahnert-Hilger G, Bigalke H . Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol. 1995; 46(1):83-96. DOI: 10.1016/0301-0082(95)00003-e. View

17.

Grunt S, Becher J, Vermeulen R . Long-term outcome and adverse effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review. Dev Med Child Neurol. 2011; 53(6):490-8. DOI: 10.1111/j.1469-8749.2011.03912.x. View

18.

De Beukelaer N, Weide G, Huyghe E, Vandekerckhove I, Hanssen B, Peeters N . Reduced Cross-Sectional Muscle Growth Six Months after Botulinum Toxin Type-A Injection in Children with Spastic Cerebral Palsy. Toxins (Basel). 2022; 14(2). PMC: 8876834. DOI: 10.3390/toxins14020139. View

19.

Ates F, Temelli Y, Yucesoy C . Intraoperative experiments show relevance of inter-antagonistic mechanical interaction for spastic muscle's contribution to joint movement disorder. Clin Biomech (Bristol). 2014; 29(8):943-9. DOI: 10.1016/j.clinbiomech.2014.06.010. View

20.

Bandholm T, Jensen B, Nielsen L, Rasmussen H, Bencke J, Curtis D . Neurorehabilitation with versus without resistance training after botulinum toxin treatment in children with cerebral palsy: a randomized pilot study. NeuroRehabilitation. 2012; 30(4):277-86. DOI: 10.3233/NRE-2012-0756. View